These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
263 related articles for article (PubMed ID: 10090237)
1. What should we expect from the next generation of antiarrhythmic drugs? Camm AJ; Yap YG J Cardiovasc Electrophysiol; 1999 Feb; 10(2):307-17. PubMed ID: 10090237 [TBL] [Abstract][Full Text] [Related]
2. Current antiarrhythmic drugs: an overview of mechanisms of action and potential clinical utility. Singh BN J Cardiovasc Electrophysiol; 1999 Feb; 10(2):283-301. PubMed ID: 10090235 [TBL] [Abstract][Full Text] [Related]
3. The molecular and ionic specificity of antiarrhythmic drug actions. Nattel S J Cardiovasc Electrophysiol; 1999 Feb; 10(2):272-82. PubMed ID: 10090234 [TBL] [Abstract][Full Text] [Related]
4. Relationship among amiodarone, new class III antiarrhythmics, miscellaneous agents and acquired long QT syndrome. Riera AR; Uchida AH; Ferreira C; Ferreira Filho C; Schapachnik E; Dubner S; Zhang L; Moffa PJ Cardiol J; 2008; 15(3):209-19. PubMed ID: 18651412 [TBL] [Abstract][Full Text] [Related]
5. A benefit-risk assessment of class III antiarrhythmic agents. Brendorp B; Pedersen O; Torp-Pedersen C; Sahebzadah N; Køber L Drug Saf; 2002; 25(12):847-65. PubMed ID: 12241126 [TBL] [Abstract][Full Text] [Related]
6. [Antiarrhythmic therapy in patients with heart failure]. Faber TS; Zehender M Ther Umsch; 2000 May; 57(5):324-32. PubMed ID: 10859993 [TBL] [Abstract][Full Text] [Related]
7. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials. Naccarelli GV; Wolbrette DL; Khan M; Bhatta L; Hynes J; Samii S; Luck J Am J Cardiol; 2003 Mar; 91(6A):15D-26D. PubMed ID: 12670638 [TBL] [Abstract][Full Text] [Related]
8. From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials. Lazzara R Am J Cardiol; 1996 Aug; 78(4A):28-33. PubMed ID: 8780326 [TBL] [Abstract][Full Text] [Related]
9. Antiarrhythmic drugs in patients with implantable cardioverter-defibrillators. Bollmann A; Husser D; Cannom DS Am J Cardiovasc Drugs; 2005; 5(6):371-8. PubMed ID: 16259525 [TBL] [Abstract][Full Text] [Related]
10. New advances in class III antiarrhythmic drug therapy. Sager PT Curr Opin Cardiol; 2000 Jan; 15(1):41-53. PubMed ID: 10666660 [TBL] [Abstract][Full Text] [Related]
11. New advances in class III antiarrhythmic drug therapy. Sager PT Curr Opin Cardiol; 1999 Jan; 14(1):15-23. PubMed ID: 9932203 [TBL] [Abstract][Full Text] [Related]
12. Antiarrhythmic and proarrhythmic properties of QT-prolonging antianginal drugs. Singh BN; Wadhani N J Cardiovasc Pharmacol Ther; 2004 Sep; 9 Suppl 1():S85-97. PubMed ID: 15378133 [TBL] [Abstract][Full Text] [Related]
13. The coming of age of the class III antiarrhythmic principle: retrospective and future trends. Singh BN Am J Cardiol; 1996 Aug; 78(4A):17-27. PubMed ID: 8780325 [TBL] [Abstract][Full Text] [Related]
15. Current and new drugs for the treatment of arrhythmias. Auer J; Berent R; Weber T; Lassnig E; Eber B Curr Opin Investig Drugs; 2002 Jul; 3(7):1029-36. PubMed ID: 12186263 [TBL] [Abstract][Full Text] [Related]
16. Antiarrhythmic drugs: a reorientation in light of recent developments in the control of disorders of rhythm. Singh BN Am J Cardiol; 1998 Mar; 81(6A):3D-13D. PubMed ID: 9537217 [TBL] [Abstract][Full Text] [Related]